Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02475213
Title Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics

head and neck squamous cell carcinoma


lung non-small cell carcinoma


MGA271 + Pembrolizumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.